Literature DB >> 9371373

In vitro kill curves of a new semisynthetic echinocandin, LY-303366, against fluconazole-sensitive and -resistant Candida species.

J A Karlowsky1, G A Harding, S A Zelenitsky, D J Hoban, A Kabani, T V Balko, M Turik, G G Zhanel.   

Abstract

In vitro killing by a new semisynthetic echinocandin, LY-303366, was characterized using clinical isolates of fluconazole-sensitive (Y58) and -resistant (Y180) Candida albicans as well as Candida glabrata (Y7) and Candida krusei (Y171). The 24-h kill curves for Y58 and Y180 demonstrated dose-independent killing of between 1 and 2 log10 with LY-303366 at concentrations of 0.1, 1, 10, 50, 100, and 1,000 times the MIC. Regrowth did not occur at 24 h with either C. albicans isolate at the aforementioned LY-303366 concentrations. At their MICs, LY-303366 and amphotericin B produced similar killing kinetics in cultures of Y58, Y180, Y7, and Y171, while all cultures exposed to fluconazole at its MIC demonstrated stasis or growth over 24 h.

Entities:  

Mesh：

Substances：

Year:  1997        PMID： 9371373      PMCID： PMC164168     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  5 in total

Review 1.  Mechanisms and clinical impact of antifungal drug resistance.

Authors:  H Vanden Bossche; D W Warnock; B Dupont; D Kerridge; S Sen Gupta; L Improvisi; P Marichal; F C Odds; F Provost; O Ronin
Journal:  J Med Vet Mycol       Date:  1994

2.  In vitro activity of a new semisynthetic echinocandin, LY-303366, against systemic isolates of Candida species, Cryptococcus neoformans, Blastomyces dermatitidis, and Aspergillus species.

Authors:  G G Zhanel; J A Karlowsky; G A Harding; T V Balko; S A Zelenitsky; M Friesen; A Kabani; M Turik; D J Hoban
Journal:  Antimicrob Agents Chemother       Date:  1997-04       Impact factor: 5.191

3.  Antifungal dynamics of LY 303366, an investigational echinocandin B analog, against Candida ssp.

Authors:  M E Ernst; M E Klepser; E J Wolfe; M A Pfaller
Journal:  Diagn Microbiol Infect Dis       Date:  1996 Nov-Dec       Impact factor: 2.803

4.  Secular trends in nosocomial primary bloodstream infections in the United States, 1980-1989. National Nosocomial Infections Surveillance System.

Authors:  S N Banerjee; T G Emori; D H Culver; R P Gaynes; W R Jarvis; T Horan; J R Edwards; J Tolson; T Henderson; W J Martone
Journal:  Am J Med       Date:  1991-09-16       Impact factor: 4.965

Review 5.  Impact of the changing epidemiology of fungal infections in the 1990s.

Authors:  M Pfaller; R Wenzel
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1992-04       Impact factor: 3.267
  5 in total
  9 in total

1.  In vitro activity of anidulafungin and other agents against esophageal candidiasis-associated isolates from a phase 3 clinical trial.

Authors:  M A Pfaller; R Hollis; B P Goldstein; S Messer; D Diekema; T Henkel
Journal:  J Clin Microbiol       Date:  2010-05-26       Impact factor: 5.948

2.  Dosage-dependent antifungal efficacy of V-echinocandin (LY303366) against experimental fluconazole-resistant oropharyngeal and esophageal candidiasis.

Authors:  V Petraitis; R Petraitiene; A H Groll; T Sein; R L Schaufele; C A Lyman; A Francesconi; J Bacher; S C Piscitelli; T J Walsh
Journal:  Antimicrob Agents Chemother       Date:  2001-02       Impact factor: 5.191

3.  Influence of human serum on antifungal pharmacodynamics with Candida albicans.

Authors:  G G Zhanel; D G Saunders; D J Hoban; J A Karlowsky
Journal:  Antimicrob Agents Chemother       Date:  2001-07       Impact factor: 5.191

4.  Pharmacokinetic and pharmacodynamic modeling of anidulafungin (LY303366): reappraisal of its efficacy in neutropenic animal models of opportunistic mycoses using optimal plasma sampling.

Authors:  A H Groll; D Mickiene; R Petraitiene; V Petraitis; C A Lyman; J S Bacher; S C Piscitelli; T J Walsh
Journal:  Antimicrob Agents Chemother       Date:  2001-10       Impact factor: 5.191

5.  In vitro fungicidal activities of echinocandins against Candida metapsilosis, C. orthopsilosis, and C. parapsilosis evaluated by time-kill studies.

Authors:  Emilia Cantón; Ana Espinel-Ingroff; Javier Pemán; Lucas del Castillo
Journal:  Antimicrob Agents Chemother       Date:  2010-02-09       Impact factor: 5.191

6.  Synergy between polyethylenimine and different families of antibiotics against a resistant clinical isolate of Pseudomonas aeruginosa.

Authors:  Hayssam Khalil; Tao Chen; Renée Riffon; Rutao Wang; Zhao Wang
Journal:  Antimicrob Agents Chemother       Date:  2008-02-19       Impact factor: 5.191

7.  In vitro activities of echinocandins against Candida krusei determined by three methods: MIC and minimal fungicidal concentration measurements and time-kill studies.

Authors:  Emilia Cantón; Javier Pemán; Amparo Valentín; Ana Espinel-Ingroff; Miguel Gobernado
Journal:  Antimicrob Agents Chemother       Date:  2009-04-20       Impact factor: 5.191

8.  Anidulafungin.

Authors:  David Murdoch; Greg L Plosker
Journal:  Drugs       Date:  2004       Impact factor: 9.546

Review 9.  Antifungal Peptides as Therapeutic Agents.

Authors:  Miguel Fernández de Ullivarri; Sara Arbulu; Enriqueta Garcia-Gutierrez; Paul D Cotter
Journal:  Front Cell Infect Microbiol       Date:  2020-03-17       Impact factor: 5.293
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.